Cargando…

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT). The development of hormone-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Xiaoyu, Flaig, Thomas W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296168/ https://www.ncbi.nlm.nih.gov/pubmed/22461790 http://dx.doi.org/10.1155/2012/978531

Ejemplares similares

Geriatric considerations in the treatment of advanced prostate cancer
por: Kessler, Elizabeth R., et al.
Publicado: (2014)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
por: Tatenuma, Tomoyuki, et al.
Publicado: (2023)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Alternaria redefined
por: Woudenberg, J.H.C., et al.
Publicado: (2013)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Redefining the Economics of Geriatric Orthopedics
por: Truntzer, Jeremy, et al.
Publicado: (2014)

Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
por: Müller, Arndt-Christian, et al.
Publicado: (2022)

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

Redefining “Natural” in Agriculture
por: Trewavas, Tony
Publicado: (2008)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
por: Mori, Keiichiro, et al.
Publicado: (2021)

Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
por: Ulm, Michael, et al.
Publicado: (2019)

Cancer: Stress Link Redefined
por: Weinhold, Bob
Publicado: (2008)

Redefining Agricultural Residues as Bioenergy Feedstocks
por: Caicedo, Marlon, et al.
Publicado: (2016)

Hyaluronic Acid: Redefining Its Role
por: Abatangelo, G., et al.
Publicado: (2020)

Is It Time to Redefine Fetal Decelerations in Cardiotocography?
por: Xodo, Serena, et al.
Publicado: (2022)

The Role of Transcriptomics in Redefining Critical Illness
por: Pelaia, Tiana M., et al.
Publicado: (2023)

Redefining serological diagnostics with immunoaffinity proteomics
por: Walter, Jonathan, et al.
Publicado: (2023)

Advanced health biotechnologies in Thailand: redefining policy directions
por: Velasco, Román Pérez, et al.
Publicado: (2013)

Redefining the Scholar-Athlete
por: Cross, Joseph L., et al.
Publicado: (2019)

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
por: Preisser, Felix, et al.
Publicado: (2021)

Health: redefined
por: Oleribe, Obinna Ositadimma, et al.
Publicado: (2018)

Redefining the role of dendritic cells in periodontics
por: Venkatesan, Gomathinayagam, et al.
Publicado: (2013)

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
por: Tamada, Satoshi, et al.
Publicado: (2018)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
por: Etheridge, Tyler, et al.
Publicado: (2019)

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review
por: Fleshner, Neil E., et al.
Publicado: (2023)

Redefining massive transfusion
por: König, Thomas C, et al.
Publicado: (2009)

Use of Prospective Multiplex Immunohistochemistry to Redefine Tissue Pathways of Diagnostic Core Biopsy of Prostate
por: Thomas, Teresa, et al.
Publicado: (2022)

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Redefining responsible research and innovation for the advancement of biobanking and biomedical research
por: Yu, Helen
Publicado: (2016)

Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer
por: Shirvani, Shervin M, et al.
Publicado: (2021)

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK
por: Rosario, Derek J., et al.
Publicado: (2016)

Redefining disease emergence to improve prioritization and macro-ecological analyses
por: Rosenthal, Samantha R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tclslml1r2lpcas6vk4tv092ec